

**CURRICULUM VITAE
OREGON HEALTH & SCIENCE UNIVERSITY**

NAME Christopher W. Ryan

DATE February 7, 2023

PRESENT POSITION AND ADDRESS

Academic Rank: Professor of Medicine
Department/Division: Medicine/Hematology Oncology
Professional Address: 3485 S Bond Ave.
Mail Code: OC14P
Portland, OR 97239
E-Mail Address: ryanc@ohsu.edu

II. EDUCATION

Undergraduate and Graduate

1994 M.D., SUNY Health Science Center at Syracuse, Syracuse, NY
1989 B.A., Cell Biology, Cornell University, College of Arts & Sciences, Ithaca, NY

Postgraduate

1997-2000 Fellowship, Section of Hematology/Oncology, University of Chicago
1994-1997 Residency, Internal Medicine, University of Chicago Hospitals, Chicago, IL

Certification

Diplomate, American Board of Internal Medicine, Medical Oncology, No: 178306
Recertification: 2021
Diplomate, American Board of Internal Medicine, No: 178306, November, 1997 (lapsed)

Licenses

State of Illinois Medical License (lapsed)
State of Oregon Medical License issued: 1/17/2003, No: MD24250, active, renewal: 12/31/2023
State of Idaho Medical License issued: 7/19/2021, No: M-15961, active, renewal: 6/30/2023

III. PROFESSIONAL EXPERIENCE

Academic

2014-present Professor, Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Portland, OR
2007-2014 Associate Professor, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR
2003-2007 Assistant Professor, OHSU, Portland, OR
2002-2003 Assistant Professor, Section of Hematology/Oncology, University of Chicago

2000-2002 Instructor, Section of Hematology/Oncology, University of Chicago
 1989-1990 Research Technician, Section of Biochemistry, Molecular and Cell Biology, Cornell University

Administrative

2013-present Executive Officer, SWOG Cancer Research Network
 2007-2010 Interim Associate Director of Clinical Research, OHSU Knight Cancer Institute
 2007-2011 Chair, OHSU Cancer Institute Clinical Research Review Committee
 2004-present OHSU Institutional Principal Investigator, SWOG
 2000-2003 Executive Officer, Cancer and Leukemia Group B (CALGB), Chicago, IL

IV. SCHOLARSHIP

Areas of Research/Scholarly Interest

Clinical trials in genitourinary cancer (renal, prostate, bladder)
 Clinical trials in sarcoma
 Quantitative imaging for cancer treatment response assessment

Awards/Honors

OHSU Knight Cancer Institute Clinical Research Scholar 2012, 2015, 2016
 OHSU Professional Staff Chair's Award for Outstanding Contributions to Development of Interdisciplinary Teams (Sarcoma Multidisciplinary Team) 2013
 National Cancer Institute Clinical Investigator Team Leadership Award 2009
 American Society of Clinical Oncology Travel Award, 2000
 Scholarship to ASCO/AACR "Methods in Clinical Cancer Research," Vail, CO, 1999
 American Society of Clinical Oncology Merit Award, 1999

Grants and Contracts

Federal (Include Title, Source, PI, Amount Period, and % Effort)

U10 CA180888 (Blanke)	04/26/2019 – 02/28/2025	effort: 22.5%
NIH/NCI	\$77,483,296 (total award amount)	

Southwest Oncology Group Site Contract

The goal of this contract is to oversee all functions of Southwest Oncology Group studies at Oregon Health & Science University as well as support the Group Chair's Office for SWOG.
 Role: Executive Officer GU, GI, Melanoma, and Early Therapeutics Committees

Publications/Creative Work

Peer-reviewed

1. Willins DA, **Ryan CW**, Platko JV, Calvo JM. Characterization of Lrp, an Escherichia coli regulatory protein that mediates a global response to leucine. J Biol Chem. 1991 Jun; 15;266(17): 10768-10774.
2. **Ryan CW**, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM: GM-CSF in combination immunotherapy for metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000 Mar; 15;88(6): 1317-1324.
3. **Ryan CW**, Shulman KL, Richards JM, et al: CI-980 in advanced melanoma and hormone refractory prostate cancer. Investigational New Drugs. 2000 May; 18(2): 187-191.
4. **Ryan CW**, Fleming GF, Janisch L, Ratain MJ. A phase I study of liposomal

- doxorubicin (Doxil) with topotecan. *Am J Clin Oncol (CCT)* 2000 Jun; 23(3): 297-300.
5. **Ryan CW**, Vogelzang NJ, Stadler WM. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon- α in patients with metastatic renal cell cancer. *Cancer*. 2002 May; 15;94(10): 2602-9.
 6. **Ryan CW**, Vokes EE, Vogelzang NJ, Janisch L, Kobayashi K, Ratain MJ. A phase I study of suramin with once or twice monthly dosing in patients with advanced cancer. *Cancer Chemother Pharmacol*. 2002 Jul; 50(1): 1-5.
 7. Park DK, **Ryan CW**, Dolan ME, Vogelzang NJ, Stadler WM. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. *Cancer Chemother Pharmacol*. 2002 Aug; 50(2): 160-2.
 8. Sahoo S, **Ryan CW**, Recant WM, Yang XJ. Angiosarcoma masquerading as embryonal carcinoma in the metastasis from a mature testicular teratoma. *Arch Pathol Lab Med*. 2003 Mar; 127(3): 360-3.
 9. Wu PC, Langerman A, **Ryan CW**, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. *Surgery*. 2003 Oct; 134(4): 656-65; discussion 665-6.
 10. Stadler WM, Huo D, George C, Yang XJ, **Ryan CW**, Karrison T, Zimmerman TM, Vogelzang NJ. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. *J Urol*. 2003 Oct; 170(4)(Pt 1): 1141-5.
 11. Davis NB, Taber DA, Ansari RH, **Ryan CW**, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. *J Clin Oncol*. 2004 Jan; 1;22(1): 115-9.
 12. Stadler WM, Cao D, Vogelzang NJ, **Ryan CW**, Hoving K, Wright R, Karrison T, Vokes EE. A randomized phase II trial of the antiangiogenic agent SU5416 in hormone refractory prostate cancer *Clin Cancer Res*. 2004 May; 15;10(10): 3365-70.
 13. **Ryan CW**, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, André AK, Wang Q. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. *Clin Cancer Res*. 2004 Jul; 1;10(13): 4406-11.
 14. Bland LB, Garzotto M, Deloughery TG, **Ryan CW**, Schuff KG, Wersinger EM, Lemmon D, Beer TM. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. *Cancer*. 2005 Feb; 15;103(4): 717-23.
 15. Gupta S, Mauer AM, **Ryan CW**, Taber DA, Samuels BL, Fleming GF. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. *Am J Clin Oncol*. 2005 Feb; 28(1): 65-9.
 16. Artz AS, Stadler WM, Vogelzang NJ, Zimmerman T, **Ryan C**. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. *Am J Clin Oncol*. 2005 Apr; 28(2): 109-13.
 17. **Ryan CW**, Stadler WM, Vogelzang NJ. A Phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. *BJU Int*. 2005 May; 95(7): 963-8.
 18. Tiffany NM, **Ryan CW**, Garzotto M, Wersinger EM, Beer TM. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. *J Urol*. 2005 Sep; 174(3): 888-92.
 19. Davis NB, **Ryan CW**, Stadler WM, Vogelzang NJ. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. *BJU Int*. 2005 Oct; 96(6): 787-90.
 20. Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M, **Ryan CW**, Janowsky JS. Testosterone loss and estradiol administration modify memory in men. *J Urol*. 2006 Jan; 175(1): 130-5.

21. Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, **Ryan CW**, Brunzell JD, Beer TM. Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. *J Lipid Res.* 2006 Feb; 47(2): 349-55.
22. **Ryan CW**, Dolan ME, Brockstein BB, McLendon R, Delaney SM, Samuels BL, Agamah ES, Vokes EE. A phase II trial of O⁶-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. *Cancer Chemother Pharmacol.* 2006 Nov; 58(5): 634-9.
23. **Ryan CW**, Huo D, Demers LM, Beer TM, Lacerna LV, and the Zometa US05 Investigators. Zoledronic acid initiated during the first year of androgen-deprivation therapy increases bone mineral density in prostate cancer patients. *J Urol.* 2006 Sep; 176(3): 972-8; discussion 978.
24. Beer TM, Venner PM, **Ryan CW**, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG. High dose calcitriol may reduce thrombosis in cancer patients. *Br J Haematol.* 2006 Nov; 135(3): 392-4.
25. Beer TM, **Ryan CW**, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. *J Clin Oncol.* 2007 Feb; 20;25(6): 669-74.
26. Beer TM, Javle MM, **Ryan CW**, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. *Cancer Chemother Pharmacol.* 2007 Apr; 59(5): 581-7.
27. Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, **Ryan CW**, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. *J Urol.* 2007 May; 177(5): 1777-81.
28. **Ryan CW**, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. *Urology.* 2007 Jul; 70(1): 122-6.
29. **Ryan CW**, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. *BJU Int.* 2007 Jul; 100(1): 70-5.
30. **Ryan CW**, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED; Southwest Oncology Group. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. *J Clin Oncol.* 2007 Aug; 1;25(22): 3296-301.
31. Montgomery RB, Nelson PS, Lin D, **Ryan CW**, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: a phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. *Cancer.* 2007 Sep; 1;110(5): 996-1002.
32. Beer TM, **Ryan CW**, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD; On Behalf of the ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. *Cancer.* 2008 Jan; 15;112(2): 326-30.
33. Ross RW, Beer TM, Jacobus S, Bublely GJ, Taplin ME, **Ryan CW**, Huang J, Oh WK; for the Prostate Cancer Clinical Trials Consortium. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are

- refractory to docetaxel. *Cancer*. 2008 Feb; 1;112(3): 521-6.
34. Blanke CD, Rankin C, Demetri GD, **Ryan CW**, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol*. 2008 Feb; 1;26(4): 626-32.
 35. Beer TM, Goldman B, Nichols CR, Petrylak DP, Agarwal M, **Ryan CW**, Crawford ED; Southwest Oncology Group. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. *Clin Genitourin Cancer*. 2008 Mar; 6(1):36-9.
 36. **Ryan CW**, Montag AG, Hosenpud JR, Samuels B, Hayden JB, Hung AY, Mansoor A, Peabody TD, Mundt AJ, Undevia S. Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. *Cancer*. 2008 Jun 1;112(11):2432-9.
 37. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, **Ryan CW**, Venner P, Ruether JD, Chi KN; and the ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. *Cancer*. 2008 Jun; 1;112(11): 2377-83.
 38. Beer TM, Goldman B, Synold TW, **Ryan CW**, Vasist LS, Van Veldhuizen PJ Jr, Dakhil SR, Lara PN Jr, Drelichman A, Hussain MH, Crawford ED. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. *Clin Genitourin Cancer*. 2008 Sep; 6(2): 103-9.
 39. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, **Ryan CW**, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnoli MM, Fletcher JA. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *J Clin Oncol*. 2008 Nov; 20;26(33): 5360-7. PMID: PMC2651078.
 40. Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, **Ryan CW**. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. *BJU Int*. 2008 Dec; 102(11): 1601-6.
 41. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, **Ryan CW**, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. *J Clin Oncol*. 2009 Jun; 10;27(17):2772-8. PMID: PMC2698016.
 42. Taplin ME, Regan MM, Ko YJ, Bublely GJ, Duggan SE, Werner L, Beer TM, **Ryan CW**, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. *Clin Cancer Res* 2009 Nov; 15;15(22): 7099-105. PMID: PMC3644858
 43. Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, **Ryan CW**, Hotte SJ, Xia C, Cupit L, Figlin RA. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced

- renal cell carcinoma sorafenib expanded access program. *Oncology*. 2010; 78(5-6):340-7.
44. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, **Ryan CW**, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. *Cancer*. 2010 Mar; 116(5): 1272-80.
 45. Beer TM, Ryan C, Alumkal J, **Ryan CW**, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. *Anticancer Drugs*. 2010 Apr; 21(4):433-8.
 46. **Ryan CW**, Vuky J, Chan JS, Chen Z, Beer TM, Nauman D. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. *Invest New Drugs*. 2011 Apr; 29(2): 374-9.
 47. von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, **Ryan CW**, Borden E. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. *Cancer*. 2012; 118(3): 770-6. PMID: PMC3576704.
 48. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, **Ryan CW**, Eisenberger MA, Mortazavi A, Bublej GJ, Taplin ME, Rosenberg JE, Kantoff PW. Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. *J Clin Oncol*. 2012 Feb; 30(5):507-12. PMID: PMC4104290.
 49. Kikuchi K, Wettach GR, **Ryan CW**, Hung A, Hooper JE, Beadling C, Warrick A, Corless CL, Olson SB, Keller C, Mansoor A. MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma. *Sarcoma*. 2013; 2013:520858. PMID: PMC373319.
 50. Alabran JL, Hooper JE, Hill M, Smith SE, Spady KK, Davis LE, Peterson LS, Malempati S, **Ryan CW**, Acosta R, Spunt SL, Keller C. Overcoming autopsy barriers in pediatric cancer research. *Pediatr Blood Cancer*. 2013 Feb; 60(2): 204-9. PMID: PMC3522778.
 51. **Ryan CW**, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis D, Kaiser C, Miller MA, Ermisch S, Ilaria Jr. R, Keohan ML. A phase II study of tasisulam sodium (LY573636 Sodium) as second-line or third line treatment for patients with unresectable or metastatic soft tissue sarcoma. *Invest New Drugs*. 2013 Feb; 31(1): 145-51.
 52. Kulesz-Martin MF, Lagowski J, Olson S, Wortham A, West T, Thomas G, **Ryan C**, Tyner JW. A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma. *Cancer Biol Ther*. 2013 Feb; 14(2):95-9. PMID: PMC3572006.
 53. Meyer JM, Perlewitz KS, Hayden JB, Doung Y-C, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afza A, Woodward WJ, Rodler ET, Jones RL, Huang W, **Ryan CW**. Phase I Trial of Preoperative Chemoradiation Plus Sorafenib for High Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates. *Clin Cancer Res*. 2013 Dec; 19(24): 6902-11. PMID: PMC3869565.
 54. Winters-Stone KM, Dobek JC, Bennett JA, Maddalozzo GF, **Ryan CW**, Beer TM. Skeletal Response to Resistance and Impact Training in Prostate Cancer Survivors. *Med Sci Sports Exerc*. 2014 Aug; 46(8): 1482-8. PMID: PMC4101037.

55. Winters-Stone KM, Dobek JC, Bennett JA, Dieckmann NF, Maddalozzo GF, **Ryan CW**, Beer TM. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. *Arch Phys Med Rehabil.* 2015 Jan;96(1):7-14. PMID: PMC4433162.
56. Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, **Ryan CW**, Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt R, Mori M. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. *Invest New Drugs.* 2015 Apr: 33(2): 480-9. PMID: PMC4390425.
57. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, **Ryan CW**, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. *Clin Genitourin Cancer.* 2015 Apr: 13(2): 113-23. PMID: PMC4418946.
58. Winters-Stone KM, Dieckmann N, Maddalozzo GF, Bennett JA, **Ryan CW**, Beer TM. Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate Cancer. *Oncol Nurs Forum.* 2015 Jul;42(4):348-56.
59. Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrlé R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, **Ryan C**, Galsky MD, Lerner SP, Posadas EM, Sonpavde G. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. *Urol Oncol.* 2016 Jan;34(1):4.e11-7.
60. Costantino C, Thomas GV, **Ryan C**, Coakley FV, Troxell ML. Metastatic renal cell carcinoma without evidence of a renal primary. *Int Urol Nephrol.* 2016 Jan;48(1):73-7. PMID: PMC4772903.
61. Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, **Ryan CW**, Protheroe A, Lusk CM, Oberg S, George DJ. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. *Lancet Oncol.* 2016 Mar;17(3):378-88.
62. **Ryan CW**, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. *J Clin Oncol.* 2016 Sep 12. pii: JCO676684. [Epub ahead of print]
63. Huang W, Beckett BR, Tudorica A, Meyer JM, Afzal A, Chen Y, Mansoor A, Hayden JB, Doung YC, Hung AY, Holtorf ML, Aston TJ, **Ryan CW**. Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. *Tomography.* 2016 Dec;2(4):308-316 PMID: PMC5215747.
64. **Ryan CW**. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma. *J Oncol Pharm Pract.* 2017 Jan;23(1):43-55. doi: 10.1177/1078155215618769. Epub 2016 Jul 9. Review. PubMed PMID: 26625878.
65. Heinrich M, Rankin C, Blanke CD, Demetri GD, Borden EC, **Ryan CW**, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors with Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. *JAMA Oncol.* 2017 Jul 1;3(7):944-952.
66. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger

- P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, **Ryan CW**, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2017 Aug;18(8):1089-1103.
67. Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, **Ryan CW**. Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas. *Ann Surg Oncol* 2018 Apr;25(4):920-927.
 68. Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, **Ryan CW**, Sternberg CN, Uzzo R, Choueiri TK, Bex A. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. *Eur Urol* 2018 May 18.
 69. Wippel B, Gundle KR, Dang T, Paxton J, Bubalo J, Stork L, Fu R, **Ryan CW**, Davis LE. Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. *Cancer Med* 2019 Jan;8 (1):111-116.
 70. Davis LE, Bolejack V, **Ryan CW**, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. *J Clin Oncol*. 2019 Jun 1;37 (16):1424-1431.
 71. Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, **Ryan CW**, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. *Cancer*. 2019 Aug 1;125(15):2610-2620.
 72. Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, **Ryan CW**, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *Lancet*. 2019 Aug 10;394(10197):478-487.
 73. Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, **Ryan CW**. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). *Kidney Cancer* 2019 3(2):111-118.
 74. Lu E, **Ryan CW**, Bassale S, Lim JY, Davis LE. Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. *Oncologist*. 2020 Feb;25(2):150-155.
 75. Berlow NE, Grasso CS, Quist MJ, Cheng M, Gandour-Edwards R, Hernandez BS, Michalek JE, **Ryan C**, Spellman P, Pal R, Million LS, Renneker M, Keller C. Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma. *Sarcoma*. 2020 May 4;2020
 76. Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, **Ryan CW**, Plets M, Blanke CD, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients With Nonpancreatic Neuroendocrine Tumors. *Clin Cancer Res*. 2020 May 15;26(10):2290-2296

77. Armstrong AJ, Nixon AB, Carmack A, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, **Ryan CW**, Protheroe A, George DJ, Halabi S. Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma. *Clin Cancer Res*. 2021 Jun 15;27(12):3317-3328\
78. Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HSL, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, **Ryan CW**, Inman BA, Mardekian J, Borham A, George DJ. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). *Cancer*. 2021 Jul 1;127(13):2204-2212
79. Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, **Ryan CW**, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. *Cancer*. 2021 Sep 1;127(17):3194-3201
80. Lue HW, Derrick DS, Rao S, Van Gaest A, Cheng L, Podolak J, Lawson S, Xue C, Garg D, White R 3rd, **Ryan CW**, Drake JM, Ritz A, Heiser LM, Thomas GV. Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma. *Cell Rep Med*. 2021 May 7;2(5):100267
81. Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, **Ryan CW**, Mardekian J, Borham A, George DJ, Harrison MR. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. *Clin Genitourin Cancer*. 2021 Jul 10;S1558-7673(21)00130-0.
82. Wagner MJ, Othus M, Patel SP, **Ryan CW**, Sangal A, Powers B, Budd G, Victor A, Hsueh C-T, Chugh R, Nair S, Leu K, Agulnik M, Sharon E, Mayerson E, Plets M, Blanke C, Streicher H, Chae YK and Kurzrock. 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). *J Immunother Cancer*. 2021 Aug;9(8):e002990
83. Halabi S, Yang Q, Carmack A, Zhang S, Foo WC, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, **Ryan CW**, Protheroe A, George DJ, Armstrong AJ. Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. *Kidney Cancer J*. 2021 Oct;19(3):64-72.
84. Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, **Ryan CW**, et al. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. *J Clin Oncol*. 2022 Apr 8;JCO2101829. doi: 10.1200/JCO.21.01829. Epub ahead of print. PMID: 35394800.
85. Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing D, Loggers ET, Livingston MB, Wright J, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, **Ryan CW**, Maki RG. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. *Cancer Med* 2022 Aug 10. Online ahead of print.

86. Feng Z, Curti BD, Quinn DI, Strother JM, Chen Z, Agnor R, Beer TM, **Ryan CW**. A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. *Clin Genitourin Cancer* 2022 May 5;S1558-7673(22)00094-5. Online ahead of print
87. Rosenbaum E, Chugh R, **Ryan CW**, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. *Eur J Cancer* 2022 Oct 7;176:155-163. doi: 10.1016/j.ejca.2022.09.003.

Non-Peer-Reviewed

1. Villano JL, **Ryan CW**. Patients presenting with CNS lesions. Case 2. Subdural presentation of recurrent breast cancer. *J Clin Oncol*. 2003 Nov; 1;21(21): 4060-2.

Chapters

1. Vogelzang NJ, **Ryan CW**: Renal cancer, in Vokes EE, Golomb HM (ed): *Oncologic Therapies*. Berlin, Springer-Verlag, 1999, pp 817-828.
2. Vogelzang NJ, **Ryan CW**: Prostate cancer, in Vokes EE, Golomb HM (ed): *Oncologic Therapies*. Berlin, Springer-Verlag, 1999, pp 765-784.
3. **Ryan CW**, Vogelzang NJ: Genitourinary cancer, in Hunter CP, Johnson KA, Muss H (ed): *Cancer in the Elderly*. New York, NY, Marcel Dekker, 2000, pp 291-324.
4. **Ryan CW**, Vogelzang NJ. Chemotherapy of genitourinary cancers, in Perry MC (ed): *The Chemotherapy Sourcebook*, 3rd ed. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 710-732.
5. **Ryan CW**, Vogelzang NJ: Renal cancer, in Vokes EE, Golomb HM (ed): *Oncologic Therapies 2nd Edition*. Berlin, Springer, 2003, pp 513-520.
6. **Ryan CW**, Vogelzang NJ: Prostate cancer, in Vokes EE, Golomb HM (ed): *Oncologic Therapies 2nd Edition*. Berlin, Springer, 2003, pp 489-497.
7. **Ryan CW**, Peabody TD: Soft tissue sarcoma, in Vokes EE, Golomb HM (ed): *Oncologic Therapies 2nd Edition*. Berlin, Springer, 2003, pp 597-608.
8. Peabody TD, **Ryan CW**: Bone sarcomas, in Vokes EE, Golomb HM (ed): *Oncologic Therapies 2nd Edition*. Berlin, Springer, 2003, pp 489-497.
9. **Ryan CW**, Schilsky RL: Role of the cooperative groups in drug development, in Budman, Calvert, Rowinsky (ed): *Handbook of Anticancer Drug Development*. Philadelphia, Lippincott Williams & Wilkins, 2003, pp 403-410.
10. Chan JS, **Ryan CW**, Vogelzang NJ: Prostate Cancer, in Hunter CP, Johnson KA, Muss HB, (ed): *Comprehensive Treatment and Management of Cancer in the Elderly*. New York, NY, Taylor and Francis, 2006, pp 249-264.
11. **Ryan CW**: Adjuvant Systemic Therapy for Renal Cell Carcinoma, in Lara PN Jr., Jonasch E (ed): *Kidney Cancer: Principles and Practice*. Heidelberg, Springer, 2012, pp 173-186.
12. **Ryan CW**: Adjuvant Systemic Therapy for Renal Cell Carcinoma, in Lara PN Jr., Jonasch E (ed): *Kidney Cancer: Principles and Practice, Second Edition*. Heidelberg, Springer, 2015, pp 229-244.

Electronic Publications

1. **Ryan CW**. Update on Renal and Bladder Cancers. Medscape Conference Coverage. June 30, 2003. Available at <http://www.medscape.com/viewarticle/457463>.
2. **Ryan CW**. Developments in the treatment of renal cancer. Medscape Conference Coverage. July 6, 2004. Available at <http://www.medscape.com/viewarticle/481670>

3. Perlewitz KS, **Ryan CW**. A Review of Neoadjuvant Chemoradiation Strategies in the Treatment of Extremity Soft Tissue Sarcomas. *The Electronic Sarcoma Update Newsletter* (peer-reviewed). April 13, 2011. Available at <http://sarcomahelp.org/articles/chemoradiation.html> (Accessed 6/15/15)
4. Meyer JM, **Ryan CW**. Clinical presentation, diagnostic evaluation, and staging of soft tissue sarcoma. *Up to Date*. May 19, 2011. Available at https://www.uptodate.com/contents/clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma?source=search_result&search=soft%20tissue%20sarcoma&selectedTitle=1~150 (accessed 2/7/2016)
5. DeLaney TF, Gebhardt MC, **Ryan CW**. Overview of multimodality treatment for primary soft tissue sarcoma of the extremities and chest wall. *Up to Date*. Jan 19, 2017. Available at: https://www.uptodate.com/contents/overview-of-multimodality-treatment-for-primary-soft-tissue-sarcoma-of-the-extremities-and-chest-wall?source=search_result&search=soft%20tissue%20sarcoma&selectedTitle=3~150 (accessed 2/7/2016)
6. DeLaney TF, Gebhardt MC, **Ryan CW**. Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities. *Up to Date*. Nov 27, 2017. Available at: https://www.uptodate.com/contents/treatment-of-locally-recurrent-and-unresectable-locally-advanced-soft-tissue-sarcoma-of-the-extremities?search=soft%20tissue%20sarcoma%20extremity%20recurrent&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 (accessed 3/23/2018)

Reviews and Editorials

1. **Ryan CW**, Herndon J, Vogelzang NJ. A review of chemotherapy for malignant mesothelioma. *Chest*. 1998 Jan: 113(1 Suppl): 66S-73S. Review.
2. **Ryan CW**, Vogelzang NJ. Gemcitabine in the treatment of bladder cancer. *Exp Opin Pharmacother* 2000 Mar: 1(3): 547-53.
3. **Ryan CW**, Vogelzang NJ, Stadler WM. Rationale for docetaxel and exisulind in hormone-refractory prostate cancer. *Advances in Prostate Cancer* 2001;5:5-7.
4. **Ryan CW**, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. *Semin Oncology*. 2001 Aug: 28(4 Suppl 15):56-61.
5. **Ryan CW**, Vogelzang NJ. Hormone-Refractory Prostate Cancer: New Horizons. 15th International Prostate Cancer Update, 2005. Vail, Colorado, Syllabus.
6. Sokoloff MH, Daneshmand S, **Ryan CW**. Current clinical trials in renal cell carcinoma. *Urol Oncol*. 2005 Jul-Aug: 23(4): 289-92. Review.
7. Beer TM, **Ryan CW**. The hazards of intermediate endpoints. *Cancer*. 2007 Nov: 1;110(9): 1877-9.
8. Israeli RS, **Ryan CW**, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. *J Urol*. 2008 Feb: 179(2): 414-23. Review.
9. **Ryan CW**. Editorial Comment on *Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer*. *J Urol*. 2009 Dec: 182(6): 2675.
10. **Ryan CW**, Jonasch E, Lara PN, Jr. Evolving Standards of Care for Advanced Renal Cell cancer. *ASCO 2010 Education Book* pp. 164-170.
11. Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, **Ryan CW**, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS. Promise and pitfalls of quantitative imaging in oncology clinical trials. *Magn Reson Imaging*. 2012 Nov: 30(9): 1301-12. PMID: PMC3466405.

12. **Ryan CW**, Desai J. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma. *Am Soc Clin Oncol Educ Book*. 2013: 2013:386-93.
13. Davis LE, **Ryan CW**. Preoperative therapy for extremity soft tissue sarcomas. *Curr Treat Options Oncol*. 2015 Jun; 16(6): 346.
14. Davis LE, **Ryan CW**. Preoperative therapy for extremity soft tissue sarcomas. *Curr Treat Options Oncol*. 2015 Jun;16(6):25.
15. **Ryan CW**. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma. *J Oncol Pharm Pract* 2017 Jan;23(1):43-55
16. **Ryan CW**. Mechanisms and funding opportunities in genitourinary cancer clinical research. *Urol Oncol* 2018 Jul 31. pii: S1078-1439(18)30192-3
17. Lu E, **Ryan CW**. ASO Author Reflections: Chemoradiation for High-Risk Soft Tissue Sarcomas. *Ann Surg Oncol* 2018 Dec;25(Suppl 3):938-939

Abstracts (selected)

1. **Ryan CW**, Vogelzang NJ, Dumas MC, et al. A phase II trial of outpatient subcutaneous GM-CSF, interleukin-2, and interferon-alpha plus oral cis-retinoic acid in patients with metastatic renal cell cancer. *J Investig Med* 1998; 46: (Abstr 274A).
2. **Ryan CW**, Vogelzang NJ, Dumas MC, et al. A phase II trial of gemcitabine (GEM) and 5-FU with IL-2 and interferon-alfa (INFA) in patients with metastatic renal cell cancer (RCC). *Proc Am Soc Clin Oncol* 1999;18 (Abstr 1264) (poster presentation).
3. **Ryan CW**, Janus TJ, Vogelzang NJ, et al. A phase I study of men and women with refractory malignancies given daily dosing of an endothelin receptor antagonist. *Proc Am Soc Clin Oncol* 2000;19 (Abstr 783) (poster presentation).
4. Dumas MC, **Ryan CW**, Dolan ME, et al. A phase II trial of oral temozolomide (TEM) with measurement of tumor O⁶-alkylguanine-DNA alkyltransferase (AGT) activity in patients (PTS) with metastatic renal cell cancer (RCC). *Proc Am Soc Clin Oncol* 2000;19 (Abstr 1479).
5. Lewis VO, Primus G, Anastassi J, Montag T, **Ryan CW**, Peabody T, Simon M, Doherty D. Oncologic Outcomes in Adults with "Primary" Lymphoma of Bone. *Musculoskeletal Tumor Society, Annual Meeting*, 2001.
6. Desai AA, Vogelzang NJ, Rini B, **Ryan CW**, Rodriguez M, Stadler WM. A Phase II Trial of Weekly Intravenous Gemcitabine (G) with Prolonged Continuous Infusion 5-Fluorouracil (F) and Oral Thalidomide (T) in Patients with Metastatic Renal Cell Cancer (mRCC). *Proc Am Soc Clin Oncol* 2001;20 (Abstr 2448).
7. **Ryan CW**, Brockstein BB, Samuels BL, et al. A Phase II Trial of O⁶-Benzylguanine (O⁶-BG) and BCNU in Patients with Advanced Soft Tissue Sarcoma (STS). *Proc Am Soc Clin Oncol* 2001;20 (Abstr 2932).
8. **Ryan CW**, Vogelzang NJ, Stadler WM. Docetaxel plus exisulind for hormone-refractory prostate cancer. *Cancer Investigation* 2002;20:72-74 (supplement 1) (oral presentation).
9. George CM, Huo D, Vogelzang NJ, Rini BI, **Ryan CW**, et al. Pooled analysis of advanced renal cell carcinoma (RCC) patients (pts) treated with gemcitabine (G) and 5-fluorouracil (F). *Proc Am Soc Clin Oncol* 2002;21 (Abstr 762).
10. Sharma S, White D, Kris M, Otterson G, Allen J, Murren J, Schiller J, Sandler A, **Ryan CW**, et al. A multicenter phase I clinical and pharmacologic study of inhaled doxorubicin (Resmycin) in adults with advanced solid tumors affecting the lungs. *Proc Am Soc Clin Oncol* 2002;21 (Abstr 1204).
11. **Ryan CW**, Schumm PL, Hansen M, et al. Early bone mineral density (BMD) loss in prostate patients undergoing androgen deprivation. *Proc Am Soc Clin Oncol* 2002;21 (Abstr 1534) (poster presentation).

12. Ratain MJ, George CM, Janisch L, Kindler HL, **Ryan CW**, et al. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002;21 (Abstr 2115).
13. Pruitt-Scott DE, **Ryan CW**, Stadler WM, et al. Exisulind (EXI) plus docetaxel (DOC) for hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2002;21 (Abstr 2460).
14. **Ryan CW**, Schumm P, Hansen M, Huo D, Stadler WM, Henderson T, Vogelzang NJ. Early bone mineral density (BMD) loss in prostate cancer patients undergoing androgen deprivation. Third North American Symposium on Skeletal Complications of Malignancy, Bethesda, MD, April 25-27, 2002, p. 89 (Abstr C5) (poster presentation).
15. Sprague E, Fleming GF, Carr R, Kindler HL, **Ryan CW**, Meek K, Hagey A, Ratain MJ. Phase I study of 21-day continuous dosing of the oral antimetabolic agent ABT-751. Proc Am Soc Clin Oncol 2003;22 (Abstr 518).
16. George CM, Desai AA, Janisch L, Kindler HL, **Ryan CW**, Vokes EE, Vogelzang NJ, Wood DL, Nadler PI, Ratain MJ. Phase I trial of erlotinib HCL (E; OSI-774) in combination with gemcitabine (G) and cisplatin (C). Proc Am Soc Clin Oncol 2003;22 (Abstr 916).
17. Davis NB, Taber DA, Ansari RH, **Ryan CW**, Vokes EE, Vogelzang NJ, Stadler WM. A phase II trial of PS-341 in patients (pts) with renal cell cancer (RCC). Proc Am Soc Clin Oncol 2003;22 (Abstr 1551)
18. Aartz AA, Stadler WM, Vogelzang NJ, Zimmerman TM, **Ryan CW**. A phase II trial of sequential chemotherapy with docetaxel and methotrexate (DM) followed by gemcitabine and cisplatin (GC) for metastatic transitional cell carcinoma of the bladder (TCC). Proc Am Soc Clin Oncol 2003;22 (Abstr 1664)
19. Murren JR, White D, Rizvi N, Kris M, Schiller J, Sandler A, **Ryan CW**, Ratain M, Pass HI, Otterson G. Phase I and pharmacokinetic trial of inhalational doxorubicin (Resmycin™). 10th World Conference on Lung Cancer, Vancouver, Canada, 2003
20. Davis NB, **Ryan CW**, Stadler WM, Vogelzang NJ. A phase II study of nilutamide in men with prostate cancer following failure of flutamide or bicalutamide therapy. Proc Am Soc Clin Oncol 2004;22 (Abstr 4669)
21. Beer TM, Bland LB, Garzotto M, **Ryan CW**, Janowsky JS. Effect of high-dose estrogen on memory in men with prostate cancer. Proc Am Soc Clin Oncol 2004;22 (Abstr 4650)
22. **Ryan CW**, Huo D, Hanson M, Stadler WM, Vogelzang NJ. Effect of zoledronic acid (ZA) versus placebo on bone mineral density (BMD) in androgen-deprived prostate cancer patients with and without bone metastases. Proc Am Soc Clin Oncol 2004;22 (Abstr 4760)
23. Tiffany NM, **Ryan CW**, Garzotto M, Wersinger EM, Beer TM. High-Dose calcitriol, docetaxel, and estramustine in androgen-independent prostate cancer (AIPC): A phase I/II study. Proc Am Soc Clin Oncol 2004;22 (Abstr 4678)
24. Higano CS, Beer TM, Garzotto M, **Ryan CW**, Pitzel M, Works CR, Hall SP. Need for awareness and monitoring of ocular toxicities (OT) due to weekly docetaxel administration: Experience during a trial of neoadjuvant docetaxel (D) and mitoxantrone (M) for patients with high-risk prostate cancer (PC). Proc Am Soc Clin Oncol 2004;22 (Abstr 4577)
25. Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, **Ryan CW**, Beer TM. Transdermal estrogen therapy improves cholesterol levels and lipid profiles in men with prostate cancer. Proc Am Soc Clin Oncol 2004;22 (Abstr 8035)
26. **Ryan CW**, Montag A, Hayden JB, Hung AY, Samuels B, Hosenpud JR, Undevia S, Peabody TD, Skoog L. Preoperative chemoradiotherapy for soft-tissue sarcomas (STS) using pathologic necrosis as a primary endpoint. Connective Tissue Oncology

- Society 10th Annual Scientific Meeting, Montreal, November, 2004, p. 29 (poster presentation).
27. Montgomery B, Lin D, **Ryan CW**, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel; a phase II study in patients with metastatic, androgen independent prostate cancer. Multidisciplinary Prostate Cancer Symposium, Orlando, February, 2005, p.176 (Abstr 283)
 28. **Ryan CW**, Huo D, Stadler WM, McWhorter LT, Vogelzang NJ. Sustained suppression of bone turnover in androgen-deprived prostate cancer (PC) patients receiving infrequent infusions of zoledronic acid (ZA). Multidisciplinary Prostate Cancer Symposium, Orlando, February, 2005, p.107 (Abstr 147)
 29. **Ryan CW**, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Early association between duration of androgen deprivation, life-style factors and bone mineral density in patients with prostate cancer: an analysis during the first 12 months of therapy. Multidisciplinary Prostate Cancer Symposium, Orlando, February, 2005, p.108 (Abstr 148)
 30. Beer TM, Hayes M, Donovan D, Emmons S, Katovic NM, Benavides M, **Ryan CW**, Liu G. Acupuncture for hot flashes in prostate cancer patients. Multidisciplinary Prostate Cancer Symposium, Orlando, FL, February 17-19, 2005, p.111 (Abstr 155)
 31. Beer TM, Garzotto M, Lowe BA, **Ryan CW**, Rarick MU, Ellis WJ, Lange PH, Takayama T, Wersinger EM, Higano CS. Weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer: results from 54 patients. Multidisciplinary Prostate Cancer Symposium, Orlando, FL, February 17-19, 2005, p.118 (Abstr 169)
 32. Beer TM, Bland LB, Garzotto M, Purnell JQ, **Ryan CW**, Deloughery TG, Wersinger EM, Lemmon D. Transdermal estradiol in androgen-independent prostate cancer (AIPC). Multidisciplinary Prostate Cancer Symposium, Orlando, FL, February 17-19, 2005, p.181 (Abstr 293)
 33. Montgomery B, Lin D, **Ryan CW**, Garzotto M, Beer T. Diethylstilbestrol and docetaxel; a phase II study in patients with metastatic, androgen independent prostate cancer. *Proc Am Soc Clin Oncol* 2005;23:437s (Abstr 4739)
 34. Hayes M, Katovic NM, Donovan D, Emmons S, Benavides M, Montalto M, **Ryan CW**, Liu G, Beer TM. Acupuncture for hot flashes in prostate cancer patients. *Proc Am Soc Clin Oncol* 2005;23:769s (Abstr 8160)
 35. **Ryan CW**, Montag A, Undevia S, Hosenpud JR, Samuels B, Hayden JB, Hung AY. Dose-intense preoperative chemotherapy with hypofractionated radiation for high-risk soft-tissue sarcoma (STS). *Proc Am Soc Clin Oncol* 2005;23:829s (Abstr 9055)
 36. Beer TM, **Ryan CW**, Venner PM, Petrylak DP, Chatta G, Ruether JD, Henner WD, Chi KN, Cruickshank S, ASCENT Investigators. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). *Proc Am Soc Clin Oncol* 2005;23:382s (Abstr 4516)
 37. Sherman ML, **Ryan CW**, Blackstein M, Mendelson D, Agarwala S, Dooley W, Dahl T, Demetri GD, STA-4783 STS Study Group. Phase 1/2 study of STA-4783, a Novel heat shock protein 70 (hsp70) Inducer, in Combination with Paclitaxel in Patient with Soft Tissue Sarcomas (STS). *Proc Am Soc Clin Oncol* 2005;23:833s (Abstr 9069)
 38. O'Brien CA, Garzotto M, Higano CS, Wersinger EM, Kaimaktchiev V, Corless CL, Lange PH, **Ryan CW**, True LD, Beer TM. Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel. *Proc Am Soc Clin Oncol* 2005;23:412s (Abstr 4640)
 39. **Ryan CW**, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Early association between duration of androgen deprivation, life-style factors and bone mineral density

- in patients with prostate cancer: an analysis during the first 12 months of therapy. American Urological Association Annual Meeting, San Antonio, TX, 2005 (Abstr 821)
40. Beer TM, **Ryan CW**, Venner PM, Petrylak DP, Chatta G, Ruether JD, Chi KN, Arroyo A, Clow F and ASCENT investigators. ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). ECCO 13, Paris, France, Oct 30 –Nov 3, 2005. European Journal of Cancer Supplements Volume 3, No. 2, October 2005, Page 232
 41. Figlin R, Bukowski R, Srinivas S, McDermott D, Dutcher J, Takimoto C, Haas N, **Ryan CW**, Hauke R, Clark, Arends R, Patel M, Lockbaum P, Huang S, Schwab G. A phase II trial of panitumumab (ABX-EGF) in the treatment of patients with metastatic renal cell carcinoma (mRCC). Fourth International Kidney Cancer Symposium, Chicago, IL 2005
 42. Baker LH, **Ryan C**, Agarwala S, Cranmer L, Blackstein M, D'Amato G, Mendelson D, Hurwitz C, McLeod M, Dahl T, Sherman MS, 4783 Sarcoma Study Group, Demetri G. Preliminary results of a phase 2 study of the novel heat shock protein 70 (hsp70) inducer, STA-4783, in combination with paclitaxel in patients with soft tissue sarcomas. 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, 2005 (Abstr B108)
 43. **Ryan CW**, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid (ZA) initiated during the first year of androgen deprivation therapy (ADT) increases bone mineral density (BMD) and suppresses bone turnover markers in prostate cancer patients. 2006 Prostate Cancer Symposium: A Multidisciplinary Approach, San Francisco, 2006 (Abstr 192)
 44. Beer TM, **Ryan CW**, Venner P, Petrylak DP, Chatta G, Ruether JD, Chi KN, Arroyo A, Clow FW. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT. 2006 Prostate Cancer Symposium: A Multidisciplinary Approach, San Francisco, 2006 (Abstr 216)
 45. Chan JS, Beer TM, Quinn DI, Garzotto M, Sokoloff M, **Ryan CW**. Phase II study of DN-101 (high dose calcitriol), mitoxantrone, and prednisone in androgen-independent prostate cancer (AIPC). 2006 Prostate Cancer Symposium: A Multidisciplinary Approach, San Francisco, February 2006 (Abstr 233)
 46. Venner PM, **Ryan CW**, Petrylak DP, Chatta G, Ruether JD, Chi KN, Curd J, Beer TM. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. 2006 Prostate Cancer Symposium: A Multidisciplinary Approach, San Francisco, 2006 (Abstr 251)
 47. Montgomery B, Lin DW, **Ryan CW**, Garzotto M, Beer TM. Diethylstilbesterol and docetaxel: a phase II study in patients with metastatic, androgen-independent prostate cancer. 2006 Prostate Cancer Symposium: A Multidisciplinary Approach, San Francisco, 2006 (Abstr 256)
 48. O'Brien CA, True LD, Higano CS, Garzotto M, Takayama T, Ellis WJ, Lange PH, Katovic NM, **Ryan CW**, Beer TM. Histologic patterns in radical prostatectomy (RP) specimens of high-risk prostate cancer patients treated with neoadjuvant chemotherapy are predictive of nodal metastases. 2006 Prostate Cancer Symposium: A Multidisciplinary Approach, San Francisco, February 2006 (Abstr 350)
 49. Oh WK, Manola J, Ross RW, Berkowitz A, **Ryan CW**, Eilers KM, Beer TM. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl), 2006: (Abstr 14533)

50. Beer TM, **Ryan CW**, Venner PM, Petrylak DP, Chatta G, Ruether J, Chi KN, Arroyo A, Clow FW. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl), 2006: (Abstr 4518)
51. Chan JS, **Ryan CW**, Venner PM, Petrylak DP, Chatta GS, Ruether J, Chi KN, Young J, Shen C, Beer TM. Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl), 2006: (Abstr 4614)
52. **Ryan CW**, Goldman BH, Lara PN, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon- α 2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl), 2006: (Abstr 4525)
53. Montgomery B, Lin C, **Ryan CW**, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: A phase II study in patients with metastatic, androgen independent prostate cancer. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl), 2006: (Abstr 4627)
54. Venner PM, **Ryan CW**, Petrylak DP, Chatta GS, Ruether J, Chi KN, Curd J, Beer TM. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl), 2006: (Abstr 4505)
55. Chan JS, Vuky J, Beer TM, **Ryan CW**. A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 in combination with imatinib mesylate in patients with previously treated advanced renal carcinoma (RCC). 5th International Kidney Cancer Symposium, Chicago, September, 2006.
56. Oh WK, Jacobus S, Ross R, Inman M, Taplin M, **Ryan CW**, Eilers K, Beer T. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. 2007 Prostate Cancer Symposium: A Multidisciplinary Approach, Orlando, February, 2007 (Abstr 238)
57. Beer TM, Lalani AS, Lee S, Eilers KM, Curd JG, Henner WD, **Ryan CW**, Venner PM, Ruether JD, Chi KN. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial. 2007 Prostate Cancer Symposium: A Multidisciplinary Approach, Orlando, February, 2007 (Abstr 220)
58. Zurita AJ, Shore N, Kozloff M, **Ryan CW**, Beer TM, Maneval EC, Chen I, Logothetis C. Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHRPC). 2007 Prostate Cancer Symposium: A Multidisciplinary Approach, Orlando, February, 2007 (Abstr 230)
59. Chan JS, Vuky J, Besaw LA, Beer TM, **Ryan CW**. A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC). *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl), 2007: (Abstr 15600)
60. Graff J, Lalani AS, Lee S, Curd JG, Henner WD, **Ryan CW**, Venner PM, Ruether JD, Chi KN, Beer TM, ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT

- trial. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl), 2007: (Abstr 5074)
61. Goldman BH, Lara PN, Beer TM, Mack PC, Drabkin HA, Holland WS, Crawford E, **Ryan CW**. Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): An analysis of SWOG 0412. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl), 2007: (Abstr 5108)
 62. Zurita AJ, Shore ND, Kozloff MF, **Ryan CW**, Beer TM, Maneval EC, Chen I, Logothetis CJ. Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa). *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl), 2007: (Abstr 5134)
 63. Knox JJ, Figlin RA, Stadler WM, McDermott DF, Gabrail N, Miller WH, Hainsworth J, **Ryan CW**, Cupit L, Bukowski RM, on behalf of the ARCCS Investigators. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl), 2007: (Abstr 5011)
 64. **Ryan CW**, Bukowski RM, Figlin RA, Knox JJ, Hutson TE, Dutcher JP, George J, Kirshner J, Humphrey J, Stadler WM, on behalf of the ARCCS Investigators. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts). *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl), 2007: (Abstr 5096)
 65. Harzstark AL, Weinberg VK, Sharib J, Smith DC, Hussain M, Beer TM, **Ryan CW**, Mathew P, Ryan CJ, Small EJ, Rosenberg JE. Second-line combination chemotherapy: a phase I trial of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC) previously treated with chemotherapy. 2008 Genitourinary Cancers Symposium: A Multidisciplinary Approach, San Francisco, February 2008 (Abstr 166)
 66. **Ryan CW**, Curti BD, Pattee KJ, Besaw L, Beer TM, Fisher B. A dose-escalation phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). 2008 Genitourinary Cancers Symposium: A Multidisciplinary Approach, San Francisco, February, 2008 (Abstr 361)
 67. Harzstark AL, Weinberg VK, Sharib J, Smith DC, Hussain MH, Beer TM, **Ryan CW**, Mathew P, Ryan CJ, Small EJ, Rosenberg JE. Second-line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC) refractory to docetaxel-based therapy. *J Clin Oncol* 26: 2008 (May 20 Suppl; Abstr 5151)
 68. Ross RW, Manola J, Oh WK, **Ryan C**, Kim J, Rastarhuyeva I, Yap JT, Van Den Abbeele AD, Kantoff PW, Taplin M. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. *J Clin Oncol* 26: 2008 (May 20 Suppl; Abstr 5069)
 69. **Ryan CW**, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, Borden EC. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. *J Clin Oncol* 26: 2008 (May 20 Suppl; Abstr 10532)
 70. Bukowski RM, Stadler WM, Figlin RA, Knox JJ, Gabrail N, McDermott DF, Cupit L, Miller WH, Hainsworth JD, **Ryan CW**, Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. Safety and efficacy of sorafenib in elderly patients (pts) ≥ 65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. *J Clin Oncol* 26: 2008 (May 20 Suppl; Abstr 5045)

71. Dunlap J, **Ryan CW**, Hung AY, Hayden JB, Mansoor A, Primary angiosarcoma of bone: report of two cases including a novel translocation. Connective Tissue Oncology Society 14th Annual Scientific Meeting, London, U.K., November 2008 (Abstr 34941)
72. Perlewitz KS, Hung AY, Koudelka CW, Hayden JB, Montag AG, Mansoor A, Hosenpud JR, Samuels B, Undevia S, **Ryan CW**, Dose-intense chemotherapy and preoperative hypofractionated radiation for high-risk soft tissue sarcomas: a multi-institutional updated analysis. Connective Tissue Oncology Society 14th Annual Scientific Meeting, London, U.K., November 2008 (Abstr 34866)
73. **Ryan CW**, Vuky J, Chan JS, Beer TM, Rothkopf M, Phase II study of everolimus (E) with imatinib (IM) in patients with previously-treated renal carcinoma (RCC). J Clin Oncol 27, 2009 (Suppl; Abstr e16075)
74. Verschraegen CF, Chawla SP, Mita MM, **Ryan CW**, Blakely L, Keedy VL, Santoro A, Buck JY, Maki RG, Lewis JJ, PICASSO Study Investigators, A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). J Clin Oncol 28:15s, 2010 (Suppl; Abstr 10004)
75. Perlewitz KS, Huang W, Hayden JB, Adler ZB, Hung A, Mansoor A, Holtorf ML, Hemmingson SL, Woodward WJ, **Ryan CW**. Sorafenib (S) with preoperative chemoradiotherapy for extremity soft tissue sarcomas (STS) and evaluation by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 28:15s, 2010 (Suppl; Abstr TPS335)
76. **Ryan CW**, Curti BD, Quinn DI, Strother JM, Chen Z, Roberson E, Beer TM, Nauman D, A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). J Clin Oncol 28:15s, 2010 (Suppl; Abstr 4528[^]); American Society of Clinical Oncologists Annual Meeting, June 2010,(Abstr 4528[^])
77. Hemmingson S, Perlewitz K, Holtorf M, Tagge I, Woodward W, **Ryan CW**, Springer C, Huang W. The Δ Ktrans DCE-MRI Parameter Provides Early Prediction of Soft-Tissue Sarcoma Therapy Response: Initial Experience. International Society for Magnetic Resonance in Medicine Annual Meeting, May 2011 (Abstr 4064)
78. Meyer JM, Perlewitz KS, Hemmingson S, Hayden JB, Hung A, Mansoor A, Holtorf ML, Woodward WJ, Huang W, **Ryan CW**. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation of preoperative therapy for extremity soft tissue sarcomas (STS). J Clin Oncol 29: 2011 (Suppl; Abstr 10098)
79. Robinson K, Roder J, Curti BD, Quinn DI, Strother JM, Grigorieva J, Roder H, **Ryan CW**. Serum Proteomics Classifies Outcome in Renal Cell Carcinoma (RCC) Patients Receiving Sunitinib and Erlotinib. 10th International Kidney Cancer Symposium; 2011 October, Chicago.
80. Meyer JM, Perlewitz KS, Hemmingson SL, Beckett B, Hayden JB; Hung A, Mansoor A, Holtorf ML, Woodward WJ, Springer CS, Huang W, **Ryan CW**. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation of preoperative therapy for extremity soft tissue sarcomas (STS). Combined meeting of the Connective Tissue Oncology Society and Musculoskeletal Tumor Society. Chicago, October, 2011 (poster #96)
81. Hahn NM, Daneshmand S, Posadas EM, Koch MO, Bihrl R, Foster R, Masterson TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, **Ryan CW**, Corless CL, Galsky MD, Alva AS, Mitchell C, Shen SS, Lerner SP, Sonpavde G. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. J Clin Oncol 30, 2012 (Suppl; Abstr 4586)
82. Meyer JM, Perlewitz KS, Hayden JB, Hung A, Doung YC, Mansoor A, Beckett B, Holtorf ML, Woodward WJ, Rodler ET, Jones RL, Huang W, **Ryan CW**. Phase I study of neoadjuvant chemoradiation (CRT) plus sorafenib (S) for high-risk extremity soft tissue sarcomas (STS). J Clin Oncol 30, 2012 (Suppl; Abstr 10011[^])

83. Meyer JM, Beckett BR, Li X, Tudorica LA, Afzal A, Hemmingson S, Chen Y, Holtorf ML, Woodward WJ, Springer CS, **Ryan CW**, Huang W. The DCE-MRI ΔK^{trans} biomarker provides early prediction of soft-tissue sarcoma response to anti-angiogenic therapy. *Proc Intl Soc Magn Reson Med* 2012;20:45.
84. Carvajal RD, Chugh R, Milhem MM, **Ryan CW**, George S, Chmielowski B, Agulnik M, Rodler ET, Elias AD, Budd GT, Tawbi H, Movva S, Van Tine BA, Dickson MA, Hensley ML, Keohan ML, Tap WD, Bennett CM, Maki RG, Schwartz GK. Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy. *American Society of Clinical Oncologists Annual Meeting, May 2012, (Abstr TPS10103)*
85. Robinson KW, Chen Y, Podolak J, Forquer K, Cook M, Thomas G, **Ryan CW**. VHL protein (pVHL) and Src expression in metastatic RCC. *J Clin Oncol* 31, 2013 (Suppl 6; Abstr 457); *Genitourinary Cancers Symposium*; Feb 2013, (Abstr 457)
86. Alumkal JJ, Slotke R, Mori M, Schwartzman J, Graff JN, Beer TM, **Ryan CW**, Koop DR, Cherala G, Munar M, Flamiatos JF, Gao L, Tucker E. Sulforaphane treatment in men with recurrent prostate cancer. *J Clin Oncol* 31, 2013 (Suppl; Abstr 5017)
87. Bubalo JS, Schnadig ID, Meyers G, Chen AI, Hayes-Lattin BM, **Ryan CW**, Digregorio J, Maziarz RT. A phase II pilot study of fosaprepitant (F) for the rescue of acute nausea and vomiting with moderately (MEC) or highly emetogenic chemotherapy (HEC) in adults. *J Clin Oncol* 31, 2013 (Suppl; Abstr e20627)
88. **Ryan CW**, Schoffski P, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Buck JY, Garcia del Muro X, Judson IR, Maki RG. PICASSO 3: A phase 3 international, randomized, double-blind, placebo-controlled study of doxorubicin (dox) plus palifosfamide (pali) vs. dox plus placebo for patients (pts) in first-line for metastatic soft tissue sarcoma (mSTS). *European Cancer Congress, Amsterdam, Netherlands, 2013 (Abstr 3802)*
89. Demetri GD, Rankin CJ, Benjamin RS, Borden EC, **Ryan CW**, Priebat DA, Tap WD, von Mehren M, Blackstein ME, Heinrich MC, Maki RG, Corless CL, Fletcher JA, Owzar K, Blanke CD. Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. *J Clin Oncol* 32:5s, 2014 (Suppl; Abstr 10508)
90. Alumkal JJ, Heiser L, Beer TM, Small EJ, Baertsch R, Stuart J, King C, Korkola J, Cetnar J, Graff JN, Thomas G, **Ryan CW**, Toschi A, Youngren J, Tucker E, Eilers K and AACR/PCF/Stand Up to Cancer West Coast Prostate Cancer Dream Team. Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer. *American Society of Clinical Oncologists Annual Meeting, May 2014 (Abstr TPS5104)*
91. Carvajal RD, Agulnik M, **Ryan CW**, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H A-H, Elias AD, Read WL, Budd GT, Hirman J, Weiden P, Bennett CM, Livingston PO, Hansen D, Maki RG, Schwartz GK, Chugh R. Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial. *J Clin Oncol* 32:5s, 2014 (Suppl; Abstr 10520)
92. Armstrong AJ, Broderick S, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, **Ryan CW**, Protheroe A, Lusk CM, Oberg S, Halabi S, George DJ. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). *American Society of Clinical Oncologists Annual Meeting, May 2015, (Abstr 4507)*

93. **Ryan CW**, Holtorf ML, Afzal A, Chen Y, Beckett BR, Mansoor A, Hayden J, Hung AY, Doung Y, Davis L, Huang W. Quantitative Dynamic Contrast-Enhanced (DCE) MRI Predicts Response to Preoperative Therapy in Extremity Soft Tissue Sarcoma (STS). Connective Tissue Oncology Society Annual Meeting, Nov 2015, (Abstr 2338741)
94. Schuetze S, Patel S, von Mehren M, **Ryan CW**, Milhem MM, Van Tine BA, McCarthy SA, Wang GC, Marquez L, Parekh TV, Knoblauch RE, Demetri GD. Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (Pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy. J Clin Oncol. 2016 Jun; 34(Suppl): Abstr 11060
95. Luo Jia, Podolak J, Degnin C, Chen Yiyi, Robinson KW, Pukay M, Schilling A, Poage C, Thomas GV, **Ryan CW**. Expression of VHL and SRC in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2016 Jun; 34(Suppl: Abstr e16133)
96. Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, **Ryan CW**. Everolimus (EVE) exposure as a predictor of toxicity (TOX) in renal cell cancer (RCC) patients (Pts) in the adjuvant setting: Results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase II study (NCT01120249). J Clin Oncol. 2017 Jun; 35(Suppl: Abstr #4566)
97. Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing DA, Loggers ET, Livingston MB, Wright JA, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, **Ryan CW**, Maki RG. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 2017 Jun; 35(Suppl: Abstr #11005)
98. Doung Y, Gundle KR, Hayden J, Davis LE, **Ryan CW**. High local recurrence rate for giant cell tumor of bone after neoadjuvant denosumab treatment. Connective Tissue Oncology Society Annual Meeting, Nov 2017, Abstr #2793308
99. Lu E, Perlewitz KS, Hayden J, Hung A, Doung Y, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, **Ryan CW**. Epirubicin and ifosfamide with preoperative radiation for high-risk soft tissue sarcomas. Poster 238, 2017 CTOS Annual Meeting, Maui
100. Tap WD, Gelderblom H, Stacchiotti S, Palmerini E, Ferrari S, Desai J, Bauer S, Blay J-Y, Alcindor T, Ganjoo KN, Broto JM, **Ryan CW**, Shuster DE, Zhang L, Wang Q, Hsu H, Lin PS, Tong S, Wagner AJ. Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT). J Clin Oncol 36, 2018 (Suppl; Abstr 11502)
101. Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow WA, Wright JA, Ward JH, Rushing DA, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, **Ryan CW**, Reinke DK, Maki RG. A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study. J Clin Oncol 36, 2018 (Suppl; Abstr 11505)
102. **Ryan CW**, Davis LE, Doung Y-C, Hung AY, Hayden JB, Gundle KR, Vetto JT, Mansoor A, Beckett BR, Norr P, Bertolone-Smith S, Huang W. A phase II study of preoperative chemoradiation plus sorafenib (S) for high-risk extremity soft tissue sarcomas (STS). 2018 European Society for Medical Oncology Congress, Munich, Germany, Abstract #1614PD. Annals of Oncology, Volume 29, Issue Suppl 8, October 2018.
103. Hu-Lieskovan S, Moon J, Campos D, Grossmann KF, Sosman JA, **Ryan CW**, Wu M, Ribas A. Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716). J Clin Oncol 36, 2018 (Suppl; Abstr TPS9603).

104. Gulley JL, Borre, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Shore D, Chen L, **Ryan CW**, Heery R, Gerritsen WR, Priou F, Philip W, Kantoff PW. Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. *J Clin Oncol* 36, 2018 (Suppl; Abstr 5006)
105. Patel SP, Othus M, Chae YK, Giles F, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, **Ryan CW**, Plets M, Blanke CD, Kurzrock R. SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. *J Clin Oncol* 37, 2019 (Suppl; Abstr TPS2658)
106. Lu E, **Ryan CW**, Bassale S, Lim JY, Davis L E. Interval-compressed vincristine, doxorubicin, cyclophosphamide (VAC), alternating with ifosfamide and etoposide (IE) for adults with Ewing or Ewing-like sarcoma. *J Clin Oncol* 37, 2019 (Suppl; Abstr 11025)
107. Appleman LJ, Puligandla M, Pal SK, Harris W, Agarwal N, Costello BA, **Ryan CW**, Pins M, Kolesar J, Vaena DA, Parikh RA, Hashmi M, Dutcher JP, DiPaola RS, Haas NB, Carducci MA. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). *J Clin Oncol* 37, 2019 (Suppl; Abstr 4502)
108. Patel SP, Othus M, Chae YK, Giles F, Hansel D, Singh P, Fontaine A, Shah M, Kasi A, Al Baghdadi T, Matrana M, Gatalica Z, Korn WM, Hayward J, MMcLeod C, Chen HX, Sharon E, Mayerson E, **Ryan CW**, Plets M, Blanke CD, Kurzrock R. A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort [abstract]. *AACR; Cancer Res* 2019;79(13 Suppl: Abstr CT039)
109. Davis LE, Latour E, Burch R, Park B, Davis JL, **Ryan CW**. A phase Ib study of ribociclib in combination with doxorubicin in advanced soft tissue sarcomas (aSTS). *J Clin Oncol* 38: 2020 (suppl; abstr 11548)
110. **Ryan CW**, Degnin C, Cranmer LD, Chen Y, Pollack S, Tonkinson J, Norr P, Davis LE. A randomized phase II study of gemcitabine (G) alone or with pazopanib (P) in refractory soft tissue sarcoma (STS). *J Clin Oncol* 38: 2020 (suppl; abstr 11515)
111. **Ryan CW**, Tangen C, Heath EI, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Vogelzang NK, Thompson IM, Lara PN. EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study. *Journal of Clinical Oncology* 2022 40:17_suppl, LBA4500-LBA4500.

Invited Lectures, Conference Presentations or Professorships

International and National

1. *Early Stage Bladder Cancer: Adjuvant and Neoadjuvant Therapy*. Oral presentation, JHGA Bladder Cancer Investigator Meeting, Eli Lilly and Company, Dublin, Ireland, August, 1998.
2. *A phase II trial of outpatient subcutaneous GM-CSF, interleukin-2 and interferon-alpha plus oral cis-retinoic acid in patients with metastatic renal cell cancer*. Poster presentation, Central Society for Clinical Research, Chicago, IL, September 19, 1998.
3. *Bladder cancer: management of metastatic and locally advanced disease*. Oral presentation, Institute for Continuing Healthcare Education, University Hospitals of Cleveland, 1999.
4. *A phase II trial of gemcitabine (GEM) and 5-FU with IL-2 and interferon-alfa (INFA) in*

- patients with metastatic renal cell cancer.* Poster presentation, American Society of Clinical Oncology, Atlanta, May, 1999.
5. *GM-CSF in combination immunotherapy for metastatic renal cell carcinoma (RCC).* Poster presentation, PROLEUKIN® Second International Congress, San Francisco, July 30, 1999.
 6. *Hormone-refractory prostate cancer.* Oral presentation, Aventis Pharmaceuticals, Metropolitan Club, Chicago, April, 2000.
 7. *A phase I study of men and women with refractory malignancies given daily dosing of an endothelin receptor antagonist.* Poster presentation, American Society of Clinical Oncology, New Orleans, May, 2000.
 8. *Docetaxel plus exisulind in hormone-refractory prostate cancer.* Oral presentation, Aventis Pharmaceuticals Investigators Meeting, Lake Tahoe, September, 2000.
 9. *Docetaxel plus exisulind in hormone-refractory prostate cancer* Poster Presentation, CaP CURE Seventh Annual Scientific Retreat, Lake Tahoe, September, 2000.
 10. *Prostate cancer – an overview,* CRA Educational Workshop, CALGB Fall Group Meeting, Chicago, November, 2000.
 11. *Chemotherapy for metastatic bladder cancer,* Holy Cross Hospital Tumor Board, Chicago, November, 2000.
 12. *Hormone-refractory prostate cancer,* Cook County Hospital, Chicago, IL, March 8, 2001.
 13. *Targeted anti-cancer therapy: The “GIST” of the story.* Grand Rounds, University of Chicago, Chicago, May, 2001.
 14. *Docetaxel plus Exisulind for hormone refractory prostate cancer.* Oral Presentation, Cell Pathways, Anaheim, June, 2001.
 15. *STI-571 for gastrointestinal stromal tumors.* Television interview, WGN News, Chicago, June, 2001.
 16. *Hormone-refractory prostate cancer.* Oral presentation, Us-Too! Chicagoland Golf Classic, July, 2001.
 17. *Bladder cancer: locally advanced and metastatic disease,* CME activity, Mt. Vernon, IL, August, 2001.
 18. *Targeted therapy for gastrointestinal stromal tumors,* Holy Cross Hospital Tumor Board, Chicago, September, 2001.
 19. *Exisulind in prostate cancer,* Chemotherapy Foundation Symposium XIX, New York, November, 2001.
 20. *Imatinib mesylate: The “GIST” of the story,* Cook County Hospital, Chicago, January, 2002.
 21. *Chemotherapy approaches for prostate cancer,* Challenging Cases in Urology, Miami, February, 2002.
 22. *Imatinib mesylate: The “GIST” of the story.* Oncology Grand Rounds, Rush-Presbyterian-St. Lukes Medical Center, Chicago, February, 2002.
 23. *Recent advances in treatment strategies for prostate cancer,* North Shore University Hospital, Roslyn, NY, April, 2002.
 24. *Hormone refractory prostate cancer,* Aventis Pharmaceuticals advisory board, Cleveland, May, 2002.
 25. *Hormone refractory prostate cancer,* CME activity, Salt Lake City, May, 2002.
 26. *Hormone refractory prostate cancer,* Aaron Scholnik Memorial Lecture, Marquette Hospital, Marquette, MI, May, 2002.
 27. *Imatinib mesylate: the “GIST” of the story,* Novartis Oncology Advisory Board, Gainesville, June, 2002.
 28. *Advanced prostate cancer,* CME activity, Oak Brook, IL, June, 2002.
 29. *Chemotherapy for prostate cancer,* CME activity, Cleveland, August, 2002.

30. *Imatinib mesylate: the "GIST" of the story*, Novartis Oncology Advisory Board, Chicago, September, 2002.
31. *Chemotherapy for prostate cancer*, CME activity, Chicago, IL, October 10, 2002.
32. *Hormone refractory prostate cancer*, Tampa Bay Physician's Journal Club, Tampa, November, 2002.
33. *Advances in the systemic treatment of prostate cancer*, International Urology Network, Minneapolis, November, 2002.
34. *Advances in the systemic treatment of prostate cancer*, Martin Memorial Hospital Tumor Board, Stuart, FL, December, 2002.
35. *Advances in the systemic treatment of prostate cancer*, International Urology Network, Grand Rapids, MI, January, 2003.
36. *Advances in the systemic treatment of prostate cancer*, Fargo, ND, January, 2003.
37. *Advances in the systemic treatment of prostate cancer*, Napa, CA, April, 2003
38. *Chemotherapeutic strategies for prostate cancer*, University of Miami G.U. Tumor Board, Miami, May, 2003
39. *Advances in strategies for prostate cancer*, Rex Healthcare Foundation, Raleigh, NC, May, 2003.
40. *Advances in the treatment of prostate cancer: ASCENT and others*, Albuquerque, July, 2003.
41. *Bone metastases in kidney cancer*, Kidney Cancer Association Survivors and Patients Conference, Chicago, July, 2003.
42. *Advances in systemic therapy for prostate cancer*, Burbank, CA, July, 2003.
43. *Advances in systemic therapy for prostate cancer*, St. Paul Hospital Tumor Board, Dallas, August, 2003.
44. *Advances in systemic therapy for prostate cancer*, Sacramento, August, 2003.
45. *Advances in systemic therapy for prostate cancer*, Montana Cancer Consortium conference, Big Sky, MT, September, 2003.
46. *Advances in the treatment of prostate cancer: ASCENT and others*, Fort Collins and Colorado Springs, September, 2003.
47. *Advances in systemic therapy for prostate cancer*, Costa Mesa, CA, October, 2003.
48. *Advances in systemic therapy for prostate cancer*, Melbourne, FL, October, 2003.
49. *Hormone-refractory prostate cancer: medical oncologist perspective*, Aventis oncology consultant meeting, Orlando, October, 2003.
50. *Advances in systemic therapy for prostate cancer*, Kaiser-Permanente, Santa Clara, February, 2004.
51. *Advances in advanced prostate cancer*. Oncology Symposium, Doctors Medical Center of Modesto, Monterey, April 2004.
52. *SWOG 0412: a phase II study of BAY 43-9006 with interferon for advanced renal cancer*, CTEP Early Drug Development Meeting, Bethesda, March, 2005.
53. *Skeletal complications across the cancer continuum: prostate cancer*. CME Lecture, Reno, June 2005.
54. *Prostate cancer and bone health*. IUN Advisory Board, Santa Monica, August, 2005.
55. *Skeletal complications across the cancer continuum: prostate cancer*. CME Lecture, Denver, October 2005.
56. *Skeletal complications across the cancer continuum: prostate cancer*. CME Lecture, New York, November, 2005.
57. *Chemotherapeutic approaches in hormone refractory prostate cancer*, Current Trends in Kidney, Bladder & Prostate Cancer CME program, Dallas, November, 2005.
58. *Molecular Targeted Therapies for Renal Cell Carcinoma: The Role of Multi-Kinase Inhibitors and Other Novel Agents*, CME program, Boise, March, 2006.
59. *Prostate cancer and bone health*. IUN Advisory Board, San Francisco, CA, April 1,

- 2006.
60. *Targeted Therapies Hit Their Mark: An Update on Advances with Multikinase Inhibitors in Renal Cell Carcinoma*, CME program, Chicago, June, 2006.
 61. *Combination Therapy: Sorafenib plus Interferon- α* , 5th International Kidney Cancer Symposium, Chicago, September, 2006.
 62. *State of the art: Advanced Renal Carcinoma*, 7th Annual Advances in Oncology, UC Davis Health System, Sacramento, September, 2006.
 63. *Fine-Tuning Chemotherapy for Liposarcoma and Leiomyosarcoma*, Discussant - Sarcoma Poster Discussion, American Society of Clinical Oncology Annual Meeting, Orlando, May, 2009.
 64. *Systemic Therapies in Advanced Renal Cell Cancer: Current Status*, Education Session, American Society of Clinical Oncology Annual Meeting, Chicago, June, 2010.
 65. *Sarcoma*, Best of ASCO, San Francisco, July, 2010.
 66. *Personalized Treatment for Metastatic RCC: The Role of Temsirolimus*. Pfizer Oncology Symposium RCC, Tokyo, September, 2010.
 67. *Selecting RCC Therapy: Piecing Together the Puzzle*, Discussant – GU Poster Discussion, American Society of Clinical Oncology Annual Meeting, Chicago, June, 2012.
 68. *Highlights of the Day: Sarcoma*, American Society of Clinical Oncology Annual Meeting, Chicago, June, 2012.
 69. *Global Management of RCC*. First Belgian Consensus Meeting of Renal Cell Carcinoma: A Belgian Society of Medical Oncology Initiative, Brussels, June, 2012.
 70. *Sarcoma*, Best of ASCO, San Diego, August, 2012.
 71. *Where Have We Been and Where Are We Going: Cytotoxic Chemotherapy for Soft-Tissue Sarcoma*, Education Session, American Society of Clinical Oncology Annual Meeting, Chicago, June, 2013.
 72. *PICASSO 3: A phase 3 international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide (pali) vs. doxorubicin plus placebo for patients in first-line for metastatic soft tissue sarcoma (mSTS)*. European Cancer Congress, Amsterdam, Oct, 2013.
 73. *“Progression”: Could Worse be Better in Metastatic RCC?* ASCO/ASTRO/SUO Genitourinary Cancers Symposium, Orlando, February, 2015
 74. Panelist, *Soft Tissue Sarcoma Tumor Board*. Society of Surgical Oncology Annual Cancer Symposium, Seattle, March, 2017.
 75. *Innovation in SWOG Clinical Trials*, Plenary Session, SWOG Spring Group Meeting, San Francisco, April, 2017.

Regional and Local

1. *Kidney cancer: an update*, Oregon Health Sciences University, Portland, OR, September, 2002.
2. *Treatment advances for prostate cancer*, Portland, April, 2003.
3. *Advances in the systemic treatment of prostate cancer*, International Urology Network, Seattle, May, 2003.
4. *Advances in the systemic treatment of prostate cancer*, Bend, OR, June, 2003.
5. *ASCO 2003: Kidney, Bladder, Sarcoma*, OHSU ASCO Review, Portland, OR, June 20, 2003.
6. *Bone Health in Prostate Cancer,” Northwest Prostate Cancer Symposium*, Portland, OR, June, 2003.
7. *Kidney Cancer: Treating the Untreatable*, Oregon Health & Science University, Department of Medicine Grand Rounds, August, 2003.
8. *Bone complications and treatment of advanced prostate cancer*, Medford, OR,

- September, 2003.
9. *"Kidney cancer" and "Soft tissue sarcomas: anything new?"* Oregon Health & Science University GU/Sarcoma Conference, Bandon, OR, October, 2003.
 10. *Male osteoporosis and other side effects of treatment*, Prostate Cancer: Hope for Today and Tomorrow, Oregon Health & Science University, Portland, OR, November, 2003.
 11. *Treatment of advanced prostate cancer*, Good Samaritan Regional Medical Center, Corvallis, OR, February, 2004.
 12. *Bone health in prostate cancer*. American Cancer Society *Man to Man* support group, McMinnville, OR, April, 2004.
 13. *ASCO 2004: Kidney, Bladder, Sarcoma*, OHSU ASCO Review, Portland, OR, June, 2004.
 14. *Bone Health in Prostate Cancer*, Northwest Prostate Cancer Symposium," Mountlake Terrace, WA, June, 2004.
 15. *Adjuvant strategies for soft tissue sarcomas*, Oncology Grand Rounds, Legacy Good Samaritan Hospital, Portland, OR, July, 2004
 16. *Bone complications of prostate cancer*, Orthopedic Grand Rounds, Oregon Health & Science University, Portland, OR, October, 2004
 17. *Advances in advanced prostate cancer*. Richland, WA, February, 2005.
 18. *ASCO Review 2005: Kidney, Bladder, Sarcoma*, OHSU ASCO Review, Portland, OR, June, 2005.
 19. *Skeletal complications across the cancer continuum: prostate cancer*. CME Lecture, Portland, OR, July, 2005.
 20. *Prostate cancer and bone health*. IUN Advisory Board, Seattle, September, 2005.
 21. *Bone Health in Prostate Cancer*, Northwest Prostate Cancer Symposium, Portland, OR, September, 2005.
 22. *Renal cell carcinoma: a new age of treatment options*, Oncology Grand Rounds, Good Samaritan Hospital, Portland, OR, November, 2005
 23. *Renal cell carcinoma*, Oncology Grand Rounds, Meridian Park Hospital, Tualatin, OR, November, 2005
 24. *Role of systemic therapy in kidney cancer*, Northwest Urological Society Meeting, Portland, OR, December, 2005
 25. *Molecular Targeted Therapies for Renal Cell Carcinoma: The Role of Multi-Kinase Inhibitors and Other Novel Agents*, CME program, Bend, OR, January, 2006.
 26. *Molecular Targeted Therapies for Renal Cell Carcinoma: The Role of Multi-Kinase Inhibitors and Other Novel Agents*, CME program, Seattle, February, 2006.
 27. *Molecular Targeted Therapies for Renal Cell Carcinoma: The Role of Multi-Kinase Inhibitors and Other Novel Agents*, CME program, Richland, WA, February, 2006.
 28. *Molecular Targeted Therapies for Renal Cell Carcinoma: The Role of Multi-Kinase Inhibitors and Other Novel Agents*, CME program, Tacoma, WA, February, 2006.
 29. *Bone health in prostate cancer*. American Cancer Society *Man to Man* support group, Milwaukie, OR, February, 2006.
 30. *Advances in renal cell carcinoma*. Medical Grand Rounds, St. Vincent's Hospital, Portland, OR, February, 2006.
 31. *Molecular Targeted Therapies for Renal Cell Carcinoma: The Role of Multi-Kinase Inhibitors and Other Novel Agents*, CME program, Eugene, OR, February, 2006.
 32. *Molecular Targeted Therapies for Renal Cell Carcinoma: The Role of Multi-Kinase Inhibitors and Other Novel Agents*, CME program, North Bend, OR, March, 2006.
 33. *Molecular Targeted Therapies for Renal Cell Carcinoma: The Role of Multi-Kinase Inhibitors and Other Novel Agents*, CME program, Corvallis, OR, April, 2006.
 34. *Targeted Therapies Hit Their Mark: An Update on Advances with Multikinase Inhibitors*

- in Renal Cell Carcinoma*, CME program, Portland, OR, June, 2006.
35. *ASCO Review 2006: Kidney, Bladder, Sarcoma*, OHSU ASCO Review, Portland, OR, June, 2006.
 36. *Bone Health in Prostate Cancer*, 6th Annual Northwest Prostate Cancer Symposium, Mountlake Terrace, WA, September, 2006.
 37. *Renal Carcinoma*, Salem Hospital Oncology Education Series, Salem, OR March, 2007.
 38. *New Agents in Advanced Prostate Cancer*, 7th Annual Northwest Prostate Cancer Symposium, Portland, OR, September, 2007.
 39. *Medical Advances in Management of Metastatic Bone Disease*, Surgical Grand Rounds, Oregon Health & Science University, Portland, OR, January, 2008.
 40. *Medical Advances in Management of Metastatic Bone Disease*, Emergency Medicine Grand Rounds, Oregon Health & Science University, Portland, OR, March, 2008.
 41. *Sarcoma*. 2008 ASCO Review. Providence Hospital, Portland, OR, June, 2008.
 42. *Multi-Modality Strategies in the Treatment of Soft Tissue Sarcomas*, OHSU Pediatric Oncology Tumor Board, Portland, OR, February, 2009
 43. *Renal Cell Carcinoma*, Internal Medicine Grand Rounds, Madigan Army Medical Center, Ft. Lewis, WA, April, 2010
 44. *Updates in Sarcoma*, Oncology Grand Rounds, Legacy Good Samaritan Hospital, Portland, OR, June, 2010
 45. *Monday Morning Journal Club*, Hem/Onc Fellow-Faculty Journal Club/Research Conference, OHSU, Portland, OR, November, 2010
 46. *Monday Morning Journal Club*, Hem/Onc Fellow-Faculty Journal Club/Research Conference, OHSU, Portland, OR, October, 2011
 47. *GU Malignancies*, Hem/Onc Fellows Conference, OHSU, Portland, OR, April, 2012
 48. *GU Malignancies*, Hem/Onc Fellows Conference, OHSU, Portland, OR, May, 2012
 49. *Clinical Management of Sarcomas 2012: What Pathologists Should Know*. Pacific Northwest Society of Pathologists 2012 Spring Meeting, Portland, OR, May, 2012
 50. *Soft Tissue Sarcomas: A Multi-Disciplinary Approach*. Tumor Board, Rogue Valley Medical Center, Medford, OR, November, 2012
 51. *Sarcoma*, Hem/Onc Fellows Grand Rounds, OHSU, Portland, OR, February, 2013
 52. *Childhood Sarcomas*. Advanced Topics in Cancer Biology, Cell616 Lecture, OHSU, Portland, OR, April, 2013
 53. *Monday Morning Journal Club*, Hem/Onc Fellow-Faculty Journal Club/Research Conference, OHSU, Portland, OR, December, 2013
 54. *Monday Morning Journal Club*, Hem/Onc Fellow-Faculty Journal Club/Research Conference, OHSU, Portland, OR, March, 2014
 55. *Soft Tissue and Bone Sarcomas*, Advanced Topics in Cancer Biology, Cell616 Lecture, OHSU, Portland, OR, April, 2014
 56. *Sarcoma*, Hem/Onc Fellows Grand Rounds, OHSU, Portland, OR, April, 2014
 57. *RCC*, Hem/Onc Fellows Grand Rounds, OHSU, Portland, OR, May, 2014
 58. *Untitled*, Hem/Onc Fellows Grand Rounds, OHSU, Portland, OR, March, 2015
 59. *Sarcomas*. Advanced Topics in Cancer Biology, Cell616 Lecture, OHSU, Portland, OR, April, 2015
 60. *Monday Morning Journal Club*, Hem/Onc Fellow-Faculty Journal Club/Research Conference, OHSU, Portland, OR, May, 2015

V. SERVICE

Membership in Professional Societies:

American Society of Clinical Oncology

Children's Oncology Group
Connective Tissue Oncology Society
Oregon Medical Association
Sarcoma Alliance for Research through Collaboration
SWOG

Granting Agency Review Work

EORTC Independent Data Safety Monitoring Committee (independent review) (2013)
Austrian Science Fund (FWF) (2013)
Randomized Controlled Trials Committee of Canadian Institutes of Health Research
Society for Surgical Oncology – fellowship site visit

Editorial and Ad Hoc Review Activities

Editorial Board:

Critical Reviews in Oncology/Hematology
EORTC Protocol Review
Urology

Ad Hoc Journal Reviewer:

Aging Health
BioMed Central Cancer
Cancer
Cancer Chemotherapy and Pharmacology
Cancer Investigation
Clinical Cancer Research
Clinical Genitourinary Cancer
Clinical Prostate Cancer
Current Clinical Pharmacology
Current Urology
Drugs of Today
Expert Opinion on Emerging Drugs
Expert Review of Anticancer Therapy
Head and Neck
Indian Journal of Urology
Investigational Drugs Database
Investigational New Drugs
Journal of Clinical Oncology
Journal of Urology
Lancet Oncology
Medical Oncology
New England Journal of Medicine
The Oncologist
Osteoporosis International
Patient Preference and Adherence

Committees

International/National

2013-present	Executive Officer, Early Therapeutics and Rare Cancers Committee, SWOG Cancer Research Network
2013-present	Executive Officer, Melanoma Committee, SWOG
2013-present	Executive Officer, Gastrointestinal Committee, SWOG

2013-present	Executive Committee, SWOG
2010-2013	ASCO Scientific Program Committee: Sarcoma Track (Track Leader)
2004-2019	Board of Governors, SWOG
2003-present	Genitourinary Committee, SWOG
2003-2007	Intergroup Coalition against Sarcoma
2001-2004	Sarcoma Working Group, American College of Surgeons Oncology Group
2000-2003	Executive Committee, Cancer and Leukemia Group B

Institutional

2019-present	OHSU Division Hem/Med Onc Compensation Committee
2012	Melanoma Search Committee
2010-2015	Division of Hematology/Oncology Fellowship Selection Committee
2010-present	Knight Cancer Institute Clinical Research Resource Allocation Committee
2008-2010	OHSU Cancer Institute Salem Affiliation Executive Committee
2007-2008	Inpatient EPIC Implementation Task Force
2006-2007	Research Pharmacy Task Force
2003-2018	Cancer Institute Clinical Research Review Committee (Chair 2007-2011)

Community Service:

2009-2013	Board of Governors, Northwest Sarcoma Foundation
-----------	--

See "Community and Patient Lectures" below. Community service has also included the development of a multi-disciplinary sarcoma program at OHSU, providing an integrated service for Oregon patients and physicians, previously available regionally only in Seattle.

Clinical Responsibilities (since last promotion):

Clinical responsibilities include 2 days of clinic per week (2007-2013), now 1.5 days per week (2013-current). Clinical practice is focused exclusively on sarcoma and genitourinary cancers (renal, prostate, bladder, testis). In addition, clinical responsibilities include 4-6 weeks of attending on the inpatient oncology service and OHSU oncology consult service.

VI. TEACHING**Overview of your Role as an Educator:**

Dr. Ryan provides instruction and mentoring to fellows in the Hematology & Medical Oncology program. He provides clinical teaching in the context of inpatient and outpatient medical oncology practice with a focus on treatment of genitourinary cancers and sarcoma and clinical trial development. He has served as a direct mentor in the training of fellows in clinical research. He has lectured regionally, nationally, and internationally to health care providers, patients, and lectures regularly to medical trainees and graduate students at OHSU.

Educational Publications (Selected from all publications)

1. **Ryan CW**, Herndon J, Vogelzang NJ. A review of chemotherapy for malignant mesothelioma. *Chest* 1998; 113:66S-73S.
2. Vogelzang NJ, **Ryan CW**: Renal cancer, in Vokes EE, Golomb HM (ed): *Oncologic Therapies*. Berlin, Springer-Verlag, 1999, pp 817-828.
3. Vogelzang NJ, **Ryan CW**: Prostate cancer, in Vokes EE, Golomb HM (ed): *Oncologic Therapies*. Berlin, Springer-Verlag, 1999, pp 765-784.
4. **Ryan CW**, Vogelzang NJ: Genitourinary cancer, in Hunter CP, Johnson KA, Muss H (ed): *Cancer in the Elderly*. New York, NY, Marcel Dekker, 2000, pp 291-324.

5. **Ryan CW**, Vogelzang NJ. Gemcitabine in the treatment of bladder cancer. *Exp Opin Pharmacother* 2000; 1:547-553.
6. **Ryan CW**, Vogelzang NJ. Chemotherapy of genitourinary cancers, in Perry MC (ed): *The Chemotherapy Sourcebook*, 3rd ed. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 710-732.
7. **Ryan CW**, Vogelzang NJ, Stadler WM. Rationale for docetaxel and exisulind in hormone-refractory prostate cancer. *Advances in Prostate Cancer* 2001;5:5-7.
8. **Ryan CW**, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. *Semin Oncology* 2001;28:56-61.
9. **Ryan CW**, Vogelzang NJ: Renal cancer, in Vokes EE, Golomb HM (ed): *Oncologic Therapies 2nd Edition*. Berlin, Springer, 2003, pp 513-520.
10. **Ryan CW**, Vogelzang NJ: Prostate cancer, in Vokes EE, Golomb HM (ed): *Oncologic Therapies 2nd Edition*. Berlin, Springer, 2003, pp 489-497.
11. **Ryan CW**, Peabody TD: Soft tissue sarcoma, in Vokes EE, Golomb HM (ed): *Oncologic Therapies 2nd Edition*. Berlin, Springer, 2003, pp 597-608.
12. Peabody TD, **Ryan CW**: Bone sarcomas, in Vokes EE, Golomb HM (ed): *Oncologic Therapies 2nd Edition*. Berlin, Springer, 2003, pp 587-595.
13. **Ryan CW**, Schilsky RL: Role of the cooperative groups in drug development, in Budman, Calvert, Rowinsky (ed): *Handbook of Anticancer Drug Development*. Philadelphia, Lippincott Williams & Wilkins, 2003, pp 403-410.
14. **Ryan CW**. Update on Renal and Bladder Cancers. *Medscape Conference Coverage*. June 30, 2003.
15. **Ryan CW**. Developments in the treatment of renal cancer. *Medscape Conference Coverage*. July 6, 2004. Available at <http://www.medscape.com/viewarticle/481670>
16. **Ryan CW**, Vogelzang NJ. Hormone-Refractory Prostate Cancer: New Horizons. 15th International Prostate Cancer Update, 2005. Vail, Colorado, Syllabus.
17. Sokoloff MH, Daneshmand S, **Ryan CW**. Current clinical trials in renal cell carcinoma. *Urol Oncol* 2005;23:289-292.
18. Chan JS, **Ryan CW**, Vogelzang NJ: Prostate Cancer, in Hunter CP, Johnson KA, Muss HB, (ed): *Comprehensive Treatment and Management of Cancer in the Elderly*. New York, NY, Taylor and Francis, 2006, pp 249-264
19. **Ryan CW**: Adjuvant Systemic Therapy for Renal Cell Carcinoma, in Lara PN Jr., Jonasch E (ed): *Kidney Cancer*. Heidelberg, Springer, 2012, pp 173-186.
20. Perlewitz KS, **Ryan CW**. A Review of Neoadjuvant Chemoradiation Strategies in the Treatment of Extremity Soft Tissue Sarcomas. *The Electronic Sarcoma Update Newsletter* (peer-reviewed). April 13, 2011.
21. Meyer JM, **Ryan CW**. Clinical presentation, diagnostic evaluation, and staging of soft tissue sarcoma. *Up to Date*. May 19, 2011. Available at <http://www.uptodate.com/contents/clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma> (accessed 10.28.2019)
22. Israeli RS, **Ryan CW**, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. *J Urol*. 2008 Feb;179(2):414-23.
23. **Ryan CW**. Editorial Comment on *Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer*. *J Urol* 2009 Dec;182(6):2675.
24. **Ryan CW**, Jonasch E, Lara PN, Jr. Evolving Standards of Care for Advanced Renal Cell cancer. *ASCO 2010 Education Book* pp. 164-170.
25. Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, **Ryan CW**, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS.

- Promise and pitfalls of quantitative imaging in oncology clinical trials. *Magn Reson Imaging*. 2012 Nov;30(9):1301-12
26. **Ryan CW**, Desai J. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma. *Am Soc Clin Oncol Educ Book*. 2013;2013:386-93
27. **Ryan CW**. Adjuvant Systemic Therapy for Renal Cell Carcinoma (Updated). Chapter 11. *Kidney Cancer*. Sept. 2014

Educational Conference Presentations

2003

ASCO 2003: Kidney, Bladder, Sarcoma, OHSU ASCO Review, Portland, OR
Kidney Cancer: Treating the Untreatable, OHSU Department of Medicine Grand Rounds
Kidney cancer and soft tissue sarcomas: anything new?, OHSU GU/Sarcoma Conference, Bandon, OR.

2004

Advances in advanced prostate cancer, Oncology Symposium, Doctors Medical Center of Modesto, Monterey, CA
Treatment of advanced prostate cancer, Good Samaritan Regional Medical Center, Corvallis, OR
ASCO 2004: Kidney, Bladder, Sarcoma, OHSU ASCO Review, Portland, OR
Adjuvant strategies for soft tissue sarcomas, Oncology Grand Rounds, Legacy Good Samaritan Hospital, Portland, OR
Bone complications of prostate cancer, Orthopedic Grand Rounds, OHSU

2005

A phase II study of BAY 43-9006 with IFNA for advanced renal cancer, CTEP Early Drug Development Meeting, Bethesda, MD
Skeletal complications across the cancer continuum: prostate cancer, Reno, NV
Skeletal complications across the cancer continuum: prostate cancer, Denver, CO
Skeletal complications across the cancer continuum: prostate cancer, New York, NY
Chemotherapeutic approaches in hormone refractory prostate cancer, Current Trends in Kidney, Bladder & Prostate Cancer, Dallas, TX
ASCO Review 2005: Kidney, Bladder, Sarcoma, OHSU ASCO Review, Portland, OR
Skeletal complications across the cancer continuum: prostate cancer, Portland, OR
Renal cell carcinoma: a new age of treatment options, Oncology Grand Rounds, Good Samaritan Hospital, Portland, OR
Renal cell carcinoma, Oncology Grand Rounds, Meridian Park Hospital, Tualatin, OR
Role of systemic therapy in kidney cancer, Northwest Urological Society Meeting, Portland, OR

2006

An Update on Advances with Multikinase Inhibitors in Renal Cell Carcinoma, Chicago, IL
Molecular Targeted Therapies for Renal Cell Carcinoma, Bend, OR
Molecular Targeted Therapies for Renal Cell Carcinoma, Seattle, WA
Molecular Targeted Therapies for Renal Cell Carcinoma, Richland, WA
Molecular Targeted Therapies for Renal Cell Carcinoma, Tacoma, WA
Advances in renal cell carcinoma, Medical Grand Rounds, St. Vincent's Hospital, Portland, OR
Molecular Targeted Therapies for Renal Cell Carcinoma, Eugene, OR
Molecular Targeted Therapies for Renal Cell Carcinoma, North Bend, OR

Molecular Targeted Therapies for Renal Cell Carcinoma, Boise, ID
Molecular Targeted Therapies for Renal Cell Carcinoma, Corvallis, OR
An Update on Advances with Multikinase Inhibitors in Renal Cell Carcinoma, Portland, OR
ASCO Review 2006: Kidney, Bladder, Sarcoma, OHSU ASCO Review, Portland, OR
State of the art: Advanced Renal Carcinoma, Saramento, CA

2007

Renal Carcinoma, Salem Hospital, Salem, OR
 Program Chair, *2007 OHSU Updates in Oncology*, CME Activity, Portland, OR
Renal Carcinoma: A Medical Oncologists Perspective. OHSU Urology Residents lecture series

2008

Medical Advances in Management of Metastatic Bone Disease, Surgical Grand Rounds, Oregon Health and Science University, Portland, OR, January 14, 2008.
 Program Chair, *2008 OHSU Updates in Oncology*, CME Activity, Portland, OR
Updates in Genitourinary Cancers, *2008 OHSU Updates in Oncology*, CME Activity, Portland, OR

2009

Program Chair, *2009 OHSU Updates in Oncology*, CME Activity, Portland, OR
Updates in Genitourinary Cancers, *2009 OHSU Updates in Oncology*, CME Activity, Portland, OR

2010

Systemic Therapies in Advanced Renal Cell Cancer: Current Status, Education Session, American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 5, 2010
Updates in Sarcoma, Oncology Grand Rounds, Legacy Good Samaritan Hospital, Portland, OR,
 Program Chair, *2010 OHSU Updates in Oncology*, CME Activity, Portland, OR
Updates in Sarcoma, *2010 OHSU Updates in Oncology*, CME Activity, Portland, OR
Sarcoma, Best of ASCO, San Francisco, CA, July 16, 2010

2011

Multidisciplinary Assessments in Advanced Renal Cell Carcinoma: Translating Evidence into Practice, CME Activity, Gurnee, IL, June 7, 2011
 Program Chair, *2011 OHSU Updates in Oncology*, CME Activity, Portland, OR, June 24, 2011
Updates in Genitourinary Cancer and Sarcoma. *2011 OHSU Updates in Oncology*, Portland, OR,

2012

Program Chair, *2012 OHSU Updates in Oncology*, CME Activity, Portland, OR, June 29, 2012
Updates in Genitourinary Cancer. *2012 OHSU Updates in Oncology*, Portland, OR, June 29
Sarcoma, Best of ASCO, San Diego, CA, August 10, 2012
Soft Tissue Sarcomas: A Multi-Disciplinary Approach. Tumor Board, Rogue Valley Medical Center, Medford, OR, November 7, 2012

2013

Where Have We Been and Where Are We Going: Cytotoxic Chemotherapy for Soft-Tissue

Sarcoma, Education Session, American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2, 2013

2014

Program Chair, 2014 Updates in Oncology, CME Activity, Portland OR, June 20, 2014
GU Cancer (non-prostate), 2014 Updates in Oncology, June 20, 2014

2015

"Progression": Could Worse be Better in Metastatic RCC? ASCO/ASTRO/SUO Genitourinary Cancers Symposium, Orlando, FL, February 28, 2015
Program Chair, 2015 Updates in Oncology, CME Activity, Portland OR, June 26, 2015
Genitourinary Cancer (Non-Prostate), 2015 Updates in Oncology, June 26, 2015

2018

Updates in Sarcoma, 2018 OHSU Updates in Oncology, CME Activity, Portland, OR July 20, 2018

Community and Patient Lectures

2003

Bone metastases in kidney cancer, Kidney Cancer Association Survivors and Patients Conference, Chicago, IL
Bone health in prostate cancer, Northwest Prostate Cancer Symposium, Portland, OR
Male osteoporosis and other side effects of treatment, Prostate Cancer: Hope for Today and Tomorrow, OHSU

2004

Bone health in prostate cancer, American Cancer Society *Man to Man* support group, McMinnville, OR
Bone health in prostate cancer, Northwest Prostate Cancer Symposium, Mountlake Terrace, WA

2005

Bone health in prostate cancer, Northwest Prostate Cancer Symposium, Portland, OR

2006

Bone health in prostate cancer, American Cancer Society *Man to Man* support group, Milwaukie, OR
Bone health in prostate cancer, Northwest Prostate Cancer Symposium, Mountlake Terrace, WA

2007

Navigating sarcoma treatments, Andrew Schorr's Patient Power web radio broadcast
New agents in advanced prostate cancer, Northwest Prostate Cancer Symposium, Portland, OR

2008

Bringing New Hope: Advancing Sarcoma Research and Care. Sarcoma Awareness Week Event, OHSU, July 17, Portland OR

2017

Clinical Trials: What and Why? OHSU Sarcoma Patient Education Conference, October 7,

Portland OR

Student and Trainee Lectures:

OHSU Hematology/Oncology Grand Rounds (fellows and residents)
OHSU Hematology/Oncology Research Lecture (fellows)
CELL 616 Lecture (graduate students)

Curriculum Development

OHSU Updates in Oncology CME conference
Course Chair (2007-2015)
Co-Chair 2019
Develop curriculum for the annual regional CME meeting

American Society of Clinical Oncology Scientific Committee – Sarcoma Track
Committee member (2011-2012), Track Chair (2013)
Proffer scientific abstracts for presentation at the ASCO annual meeting

American Society of Clinical Oncology Education Committee – Sarcoma Track
Liaison from ASCO Scientific Committee (2013)
Develop educational curriculum for ASCO annual meeting

Mentorship

I have served as mentor the following Hematology/Oncology fellows during their research years of fellowship:

Available upon request

Educational Leadership and Administration

Hematology Oncology Fellowship Committee
Member (2010-2013)
Invitation, interview, and selection of fellowship candidates

Also see “Curriculum Development”

Lerner Assessment

Feedback from Dr. Ryan’s CME lectures has been consistently positive. Effectiveness as a lecturer is further evidenced by ongoing and repeat requests to lecture on kidney cancer and sarcoma management at regional, national and international forums. Effectiveness in educational writing is evidenced by repeat requests to author chapters, reviews, and online publications.

Effectiveness as a mentor of trainees is evidenced by presentation and publication of research results by trainees as well as career placement in academia and industry.

Effectiveness as a teacher of students and housestaff is evidenced by positive feedback from inpatient and consult service months.